There is a growing market need for ultrasensitive immunoassays in smaller samples, beyond the limits of current standard technologies. Spear Bio is commercializing a new, ultrasensitive immunoassay platform capable of analyzing miniscule sample volumes. The platform’s technology – developed by and exclusively licensed from Harvard University – leverages 2-factor authentication and can detect down to single digit counts of proteins per sample.
Spear Bio is focused on developing high impact immunoassays that can quickly be adopted by leading academic and clinical researchers and practitioners. Our platform’s simple workflow fits within existing labs and their instruments’ installed base – with no proprietary instruments to purchase.
Ultrasensitive Immunoassays Driving Innovation
We are passionate about partnering to drive adoption of cutting-edge, high impact immunoassays.
If you would like to pilot Spear Bio’s immunoassay platform in your laboratory, please email your contact details to firstname.lastname@example.org
Jerome has spent the last two decades in life sciences and medical technology, in various leadership roles. His focus has been on driving the effective development and commercialization of innovations in both medical devices and diagnostic technologies. He spent most of this career at Medtronic, and Leica Biosystems (a Danaher company). He has an MS in engineering from the Ecole Centrale Paris in France, and an MBA from the Kellogg School at Northwestern University.
Co-founder, President & CTO
Feng has spent the last decade researching and inventing new techniques in the field of molecular and immuno-diagnostics. Before joining Spear Bio, he was the Technology Development Fellow at the Wyss Institute for Biologically Inspired Engineering at Harvard University where he invented Spear Bio's core technology. Feng received his B.S. in Chemistry & M.Phil. in Biomedical Engineering from Hunan University and his Ph.D. in Chemical and Biomolecular Engineering from Hong Kong University of Science and Technology.
Peng is a Professor in the Department of Systems Biology at Harvard Medical School. He also serves as a Core Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he co-founded Ultivue. Peng obtained his Ph.D. degree in computer science and MS in molecular cancer biology from Duke University, and a BS in biochemistry and molecular biology from Peking University.
Sr. Director, Commercial Strategy and Business Development
Oliver has spent the last decade leading business development and product management teams developing new markets and launching cutting edge, technology-driven products. Oliver most recently led program and product management teams at Thermo Fisher Scientific. He has a BS in Biological Engineering from Cornell University and an MBA from Carnegie Mellon University.
Director of Product Development
Graeme is a molecular biologist who led the development of microbial sequencing technologies as CSO of Pathogenica, and commercialized multiplexed biomarker product lines as a Director at Firefly BioWorks, which was acquired by Abcam in 2015. Graeme’s postdoctoral training at MIT and Harvard Medical School focused on non-coding RNA biology, and he holds an MBiochem in Biochemistry and DPhil in Human Genetics from Oxford University
Head of Application Development
Yu comes to Spear Bio after spending three years as a Research Fellow at the Wyss Institute for Biologically Inspired Engineering at Harvard University. At Wyss, Yu collaborated closely with Spear Bio co-founders Feng Xuan and Peng Yin on validating and applying Spear Bio’s core technology. Prior to joining Spear Bio and his tenure at the Wyss Institute, Yu obtained his PhD in Biological and Biomedical Science from Harvard Medical School and received undergraduate biology degrees from Nanjing University and the University of Southampton.